Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deputy Editor
Ireland
+10 year(s) experience
Generics Bulletin
Dr Reddy’s has become the latest firm to strike a licensing deal with Gilead for its remdesivir potential treatment for COVID-19.
Topic Coronavirus
Generics Bulletin
As Hikma launches propofol vials in three presentations in the US to address a local shortage, CEO Siggi Olafsson explains how the company is more broadly keeping on top of the higher demand generated by the coronavirus pandemic.
Topic Coronavirus
Generics Bulletin
In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.
Topic Coronavirus
Generics Bulletin
Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.
Pink Sheet
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
Topic Coronavirus
Generics Bulletin
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
Topic Coronavirus
Generics Bulletin
Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.
Topic Coronavirus
Generics Bulletin
Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.
Topic Coronavirus
Generics Bulletin
European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.
Topic Coronavirus
Generics Bulletin
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.
Generics Bulletin
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
Generics Bulletin
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
Generics Bulletin
Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.
Topic Biosimilars
Generics Bulletin
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Topic Biosimilars Strategy
Generics Bulletin
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.
Topic Company analysis
Generics Bulletin
09 Jul 2020
Generics Bulletin
08 Jul 2020
Generics Bulletin
08 Jul 2020
Generics Bulletin
06 Jul 2020
Generics Bulletin
03 Jul 2020
Generics Bulletin
03 Jul 2020
Generics Bulletin
02 Jul 2020
Generics Bulletin
02 Jul 2020
Generics Bulletin
01 Jul 2020
Generics Bulletin
30 Jun 2020
Generics Bulletin
29 Jun 2020
Generics Bulletin
26 Jun 2020
Generics Bulletin
26 Jun 2020
Generics Bulletin
25 Jun 2020
Generics Bulletin
23 Jun 2020
